Purdue Pharma

Purdue Pharma was an American pharmaceutical company whose modern history was defined by the commercialization of prescription pain medicines, especially the extended-release opioid OxyContin. The business began in 1892 as the Purdue Frederick Company and later became associated with the Sackler family, whose members acquired and controlled the company through private ownership structures. Purdue developed or marketed products in pain management, addiction treatment, and other prescription-drug categories, but its public identity ultimately became inseparable from opioid litigation and the overdose crisis in the United States. The company’s most consequential product was OxyContin, an extended-release formulation of oxycodone introduced in the United States in 1996. Purdue promoted the product as a long-acting treatment for moderate-to-severe pain. Its commercial strategy emphasized the duration of relief and encouraged broader prescribing for chronic pain. Public investigations, litigation, and later regulatory findings argued that the company’s marketing understated addiction and misuse risks and helped expand the use of opioids beyond narrowly defined acute and end-of-life settings. Purdue disputed many allegations for years, while acknowledging some misconduct in separate criminal resolutions. Purdue’s portfolio also included MS Contin, an extended-release morphine product that preceded OxyContin; Butrans, a buprenorphine transdermal system; Hysingla ER, an extended-release hydrocodone product; and opioid-use-disorder treatments including buprenorphine products sold through related operations. The company also worked on opioid-reversal and addiction-treatment medicines, including Narcan through its subsidiary Adapt Pharma and other affiliated businesses. These products placed Purdue at the intersection of pain treatment, addiction medicine, and public-health policy. From the 2000s onward, Purdue faced an expanding series of lawsuits brought by states, municipalities, Native American tribes, hospitals, insurers, and individuals. Allegations included deceptive promotion, failure to prevent diversion, and conduct that contributed to widespread opioid overprescribing. In 2007, Purdue Pharma L.P. and several executives pleaded guilty in federal court to misbranding OxyContin, agreeing to criminal and civil penalties. The company later reached additional settlements, including a 2020 criminal and civil resolution with the U.S. Department of Justice. Purdue filed for Chapter 11 bankruptcy protection in September 2019. Its proposed restructuring was designed to convert the company into a public-benefit-oriented entity whose proceeds would support opioid abatement, while releasing members of the Sackler family from many civil claims in exchange for a substantial financial contribution. The arrangement was challenged by states, tribes, municipalities, and other creditors. The U.S. Supreme Court rejected the proposed settlement in June 2024 because the bankruptcy code did not authorize the non-consensual release of claims against the Sackler family. A revised restructuring plan was later approved in September 2024, with the company expected to emerge under a new ownership and governance structure dedicated to public-health purposes. Purdue’s pre-restructuring commercial identity therefore belongs to a company that ceased ordinary operations as a conventional private pharmaceutical business, even though successor operations and products continued through the bankruptcy process.

Purdue Pharma traces its origins to the Purdue Frederick Company, established in New York in 1892 by John Purdue Gray and George Frederick Bingham. The business later came under the ownership and influence of members of the Sackler family, whose pharmaceutical interests were built through privately held companies. Purdue expanded its presence in prescription medicines and became particularly associated with controlled-release formulations designed to provide longer-lasting pain relief. One of the company’s important predecessors was MS Contin, an extended-release morphine product introduced in the 1980s. Purdue subsequently applied controlled-release technology to oxycodone and launched OxyContin in the United States in 1996. The product was promoted for moderate-to-severe pain and became a major commercial success. Purdue’s sales strategy used a large field force, promotional materials, continuing-medical-education activities, and messaging that emphasized the product’s extended duration. Critics and later government investigations argued that the company minimized the risks of addiction, abuse, and diversion, particularly as OxyContin use expanded for chronic non-cancer pain. OxyContin became one of the most widely recognized prescription opioids in the United States. As misuse and overdose rates rose, Purdue faced increasing criticism from journalists, regulators, medical researchers, patients, and public officials. In 2007, Purdue Pharma L.P. and three executives pleaded guilty to federal misbranding charges. The resolution stated that the company had represented OxyContin as less addictive, less subject to abuse, and less likely to cause withdrawal than other pain medicines. Purdue paid criminal and civil penalties, but continued selling opioid products. During the following decade, litigation broadened from individual cases to actions by states, counties, cities, tribes, hospitals, insurers, and other institutions. Plaintiffs alleged that Purdue’s marketing helped create demand for opioids and that the company failed to prevent diversion. The company denied many claims and argued that its medicines had legitimate medical uses, while the Sackler family generally denied personal liability. Purdue also diversified its activities. It sold or developed products for chronic pain and addiction treatment, and affiliated businesses became involved with buprenorphine and naloxone products, including Narcan after the acquisition of Adapt Pharma. In 2019, Purdue filed for Chapter 11 bankruptcy protection. The filing paused much of the litigation and initiated a restructuring process intended to resolve thousands of claims. The proposed plan transferred the company into a new entity designed to direct proceeds toward opioid abatement, addiction treatment, overdose prevention, and related public-health programs. It also included broad releases for Sackler family members in exchange for a multibillion-dollar contribution. Some states and other creditor groups supported the plan, while others objected that the bankruptcy process could not extinguish claims against non-bankrupt Sackler family members without the claimants’ consent. Purdue reached a separate federal criminal and civil resolution in 2020, including a guilty plea and monetary penalties. The bankruptcy plan continued to face appellate challenges. In June 2024, the U.S. Supreme Court ruled that the proposed non-consensual releases exceeded the bankruptcy court’s authority. The decision did not end the bankruptcy, but required the parties to renegotiate the arrangement. A revised plan was approved in September 2024 after increasing the Sackler contribution and removing the family’s control of the reorganized enterprise. The successor structure was intended to operate for public-health purposes rather than return the old company to ordinary private ownership. Purdue’s historical importance is therefore dual. It was a pharmaceutical developer and marketer whose products included significant pain and addiction medicines, but it also became a defining corporate subject in the history of the U.S. opioid epidemic. Its bankruptcy, criminal resolutions, civil settlements, and proposed transformation into a public-benefit-oriented entity have made it a major case study in pharmaceutical regulation, corporate accountability, mass-tort bankruptcy, and public-health remediation.

1. 2024Supreme Court blocks original restructuring settlement

   The Supreme Court ruled that the proposed bankruptcy settlement could not release claims against Sackler family members without the consent of affected claimants.

   Source
2. 2024Revised restructuring plan approved

   A bankruptcy court approved a revised plan providing for increased Sackler funding and a public-health-oriented successor structure.

   Source
3. 2020Federal criminal and civil resolution

   Purdue agreed to plead guilty to federal charges and entered a broader settlement with the U.S. Department of Justice.

   Source
4. 2019Chapter 11 bankruptcy filing

   Purdue entered bankruptcy protection as part of an effort to resolve thousands of opioid-related claims.

   Source
5. 2015Adapt Pharma acquired

   Purdue-related ownership acquired Adapt Pharma, the company associated with the naloxone nasal spray Narcan, expanding the group’s exposure to opioid-overdose response products.

   Source
6. 2010Abuse-deterrent OxyContin formulation introduced

   The FDA approved a reformulated OxyContin intended to make some forms of tampering and misuse more difficult, while noting that abuse-deterrent technology does not eliminate abuse risk.

   Source
7. 2007Federal misbranding resolution

   Purdue Pharma L.P. and three executives pleaded guilty to federal charges related to representations about OxyContin’s risks and agreed to penalties.

   Source
8. 1996OxyContin launched in the United States

   Purdue launched OxyContin, an extended-release oxycodone product that became its most commercially important and controversial medicine.

   Source
9. 1984MS Contin introduced

   Purdue introduced MS Contin, an extended-release morphine product that became an important precursor to its later controlled-release opioid strategy.

   Source
10. 1892Purdue Frederick Company founded

    John Purdue Gray and George Frederick Bingham established the company that became the historical predecessor of Purdue Pharma.

    Source

Historically positioned as a prescription pharmaceutical company focused on pain management, with later activities in addiction treatment and overdose reversal. Its commercial positioning was transformed by litigation and public scrutiny over opioid marketing and became associated primarily with the U.S. opioid crisis.

• OxyContinExtended-release opioid analgesic1996

  OxyContin is Purdue’s extended-release formulation of oxycodone. Launched in the United States in 1996, it was intended for around-the-clock treatment of moderate-to-severe pain. Its commercial expansion and marketing became central to lawsuits and investigations concerning opioid overpromotion, addiction risk, diversion, and the broader U.S. overdose crisis. A reformulated version with abuse-deterrent properties was approved in 2010.

• MS ContinExtended-release morphine analgesic1984

  MS Contin is an extended-release morphine product associated with Purdue’s early controlled-release pain-medicine business. Its development and commercialization provided technical and commercial experience that preceded the launch of OxyContin. The product was designed to provide sustained analgesia and was used in prescription pain management, including serious and chronic pain settings.

• ButransBuprenorphine transdermal analgesic

  Butrans is a transdermal buprenorphine product used for the management of pain severe enough to require an opioid analgesic. It delivers buprenorphine through a skin patch over an extended period. The product formed part of Purdue’s prescription pain portfolio and illustrates the company’s later involvement with a partial opioid agonist that also has applications in addiction medicine.

• Hysingla ERExtended-release opioid analgesic2014

  Hysingla ER is an extended-release hydrocodone product approved for severe, persistent pain requiring continuous opioid treatment. It uses an abuse-deterrent formulation intended to make certain forms of manipulation more difficult. The product represented Purdue’s continued participation in long-acting opioid medicines after scrutiny of OxyContin’s safety profile and marketing practices had intensified.

• NarcanOpioid overdose reversal2015

  Narcan is a naloxone nasal spray used to reverse opioid overdose. Purdue became associated with the product through its ownership of Adapt Pharma. Narcan was positioned as an accessible emergency intervention for opioid overdose and became an important part of the public-health response to opioid mortality. The product later moved outside Purdue’s ownership structure.

• Buprenorphine productsOpioid-use-disorder treatment

  Through related operations, Purdue participated in the development and marketing of buprenorphine-based medicines for opioid-use disorder. These products were intended to reduce withdrawal symptoms and cravings and to support treatment for people with opioid dependence. Their presence reflected a strategic shift toward addiction treatment and public-health products as scrutiny of the company’s opioid pain portfolio grew.

• 2001Pain-management awareness promotion

  United States

  Purdue participated in broader efforts to promote pain assessment and treatment, including educational and professional materials that supported expanded opioid prescribing for chronic pain.

  Outcome. The approach contributed to debate over pharmaceutical influence, medical education, and the expansion of opioid treatment beyond acute and end-of-life care.

  Source
• 1996OxyContin professional promotion

  United States

  Purdue used a large-scale professional marketing program to promote OxyContin to prescribers, emphasizing its extended duration and suitability for pain treatment. Public investigations later criticized the campaign for minimizing addiction and misuse risks.

  Outcome. The campaign helped make OxyContin a major prescription product but became a central subject of criminal, civil, regulatory, and public-health scrutiny.

  Source

• 2024Revised public-benefit restructuringStrategy

  The Supreme Court held that the earlier settlement could not release claims against non-bankrupt Sackler family members without claimant consent.

  What changed. The parties revised the restructuring to increase the Sackler contribution and remove family control of the reorganized enterprise.

  Aftermath. The approved structure was intended to direct future proceeds toward opioid abatement, addiction treatment, overdose prevention, and related public-health work.

  Source
• 2019Chapter 11 restructuringOther

  Purdue faced thousands of opioid claims and sought a centralized process for resolving litigation.

  What changed. The company filed for Chapter 11 bankruptcy protection and proposed transferring its assets into a public-health-oriented successor.

  Aftermath. The plan became the subject of years of litigation and ultimately required revision after the Supreme Court rejected the original Sackler-release provisions.

  Source
• 2010Reformulation of OxyContinGeneration change

  Purdue faced growing concern about crushing and manipulating extended-release tablets for nonmedical use.

  What changed. The company introduced a reformulated tablet designed to make some forms of tampering more difficult.

  Aftermath. The reformulation received FDA approval but did not eliminate addiction, misuse, or diversion risks and remained part of broader opioid-policy debates.

  Source
• 1996Launch of OxyContinProduct launch

  Purdue sought to expand controlled-release opioid treatment into a broader prescription pain market.

  What changed. The company introduced extended-release oxycodone under the OxyContin brand in the United States.

  Aftermath. OxyContin became a major commercial product and later the principal focus of allegations concerning opioid marketing and the overdose crisis.

  Source

• 2024Supreme Court decision on Sackler releasesControversy

  The Supreme Court rejected the original bankruptcy settlement because it would have released claims against Sackler family members without the consent of affected claimants. The decision required a revised restructuring process.

  Source
• 2020Federal criminal resolutionControversy

  Purdue agreed to plead guilty to federal criminal charges involving opioid marketing and related conduct and entered a substantial civil and criminal resolution with the Department of Justice.

  Source
• 2019Opioid litigation and bankruptcyControversy

  Thousands of opioid-related claims against Purdue led the company to seek Chapter 11 protection. The bankruptcy became a major dispute over corporate accountability and the use of bankruptcy to resolve claims against non-bankrupt owners.

  Source
• 2007OxyContin misbranding guilty pleaControversy

  Purdue Pharma L.P. pleaded guilty to federal misbranding charges based on representations that OxyContin was less addictive, less subject to abuse, and less likely to cause withdrawal than other pain medicines.

  Source

1. Purdue Pharma
2. U.S. Department of Justice: Purdue Pharma Pleads Guilty to Misbranding OxyContin
3. U.S. Department of Justice: Purdue Pharma Federal Resolution
4. U.S. Supreme Court: Harrington v. Purdue Pharma
5. FDA: Extended-Release and Long-Acting Opioid Analgesics
6. MS Contin introduced
7. OxyContin launched in the United States
8. Adapt Pharma acquired
9. Chapter 11 bankruptcy filing
10. Revised restructuring plan approved
11. Pain-management awareness promotion